Pharmaceutical pricing and market access is one of the most politically sensitive and organizationally complex functions in the industry. Pricing decisions affect patient access, payer relationships, government policy engagement, investor expectations, and competitive positioning simultaneously. Market access strategy determines whether a drug that works clinically actually reaches the patients who need it.
The pharma CEO is ultimately accountable for pricing and market access decisions that are both commercially sound and consistent with the company’s values on patient access. But the CEO cannot personally manage pricing analysis, payer negotiations, health economics modeling, or formulary placement strategies across a portfolio of products in multiple markets.
This guide addresses how to build the delegation structure that allows pricing and market access to be managed effectively without requiring CEO operational involvement.
The CEO’s Strategic Pricing Role
The pharma CEO must maintain strategic ownership of several pricing dimensions that are too consequential for full delegation:
Pricing philosophy. The CEO sets the organizational position on how the company approaches pricing: the values and principles that guide pricing decisions, the commitment to patient access programs, and the stance on pricing controversies in the policy environment. This philosophical foundation must come from the top and cannot be delegated.
Major product launch pricing. For significant new product launches, the CEO should be involved in the pricing decision because of its implications for the brand, investor expectations, political relationships, and competitive dynamics. This is not about reviewing the analytical detail; it is about making the strategic judgment that incorporates inputs beyond what the commercial team alone considers.
Public positioning on pricing policy. In an environment where drug pricing is a persistent political topic, the CEO must be prepared to represent and defend the company’s pricing approach publicly. This requires genuine ownership of the pricing strategy, not just familiarity with it.
Building the Pricing and Market Access Function
A dedicated pricing and market access function, typically led by a VP of Pricing and Market Access or Head of Global Market Access, should own the operational development and execution of pricing and access strategies.
Their responsibilities include: conducting health economic analysis supporting value demonstration, developing payer engagement strategies for each major market, managing formulary placement negotiations with payers and PBMs, building and maintaining patient assistance and access programs, monitoring and responding to pricing-related policy developments, and producing the pricing analyses that inform major pricing decisions.
The CEO manages this function through a combination of regular strategic briefings and defined decision-making touchpoints, not operational oversight of individual payer negotiations or access program logistics.
Delegating Health Economics and Outcomes Research
Health economics and outcomes research (HEOR) is the analytical foundation of market access strategy. This function produces the cost-effectiveness analyses, real-world evidence studies, and value dossiers that payers use to make formulary and reimbursement decisions.
A Head of HEOR or Health Economics Director should lead this function. They manage the health economics modeling, outcomes research study design, publication strategy for HEOR findings, and the development of value messages for different payer audiences.
The CEO is a consumer of HEOR outputs, particularly in strategic discussions about product value positioning and pricing. They are not involved in study design, modeling methodology, or publication processes.
Managing Payer Relationships at the CEO Level
In most pharmaceutical markets, payer relationship management is a function of the commercial and market access teams, not the CEO. But there are payer relationship moments where CEO engagement is appropriate: senior executive meetings with major national payers on value-based contracts or access partnerships, engagement with CMS leadership on significant reimbursement policy questions, and international reimbursement agency meetings where CEO presence signals commitment to a market.
Outside these specific moments, payer relationship management belongs to the market access and account management teams. The CEO does not attend routine formulary negotiations or payer operational meetings.
For broader context on how the commercial delegation framework connects pricing and market access to other functions, see pharma commercial strategy.
Delegating Patient Access Programs
Patient assistance programs, copay support programs, and patient affordability initiatives are an essential component of pharmaceutical market access strategy. The operational management of these programs is entirely delegatable.
A Patient Access Director or Head of Patient Services should manage patient access programs: designing the program structure, managing the eligibility and enrollment processes, coordinating with specialty pharmacy and distribution partners, and producing program performance reports.
The CEO sets the patient access program philosophy and ensures that access commitments are genuine rather than reputational. They review patient access program reach and impact data at a portfolio level. They do not manage individual program applications or operational details.
Market Access in Launch Planning
For products approaching commercial launch, market access strategy development must begin years before launch. This early market access work, including early payer engagement, dossier development, and pricing research, should be delegated to the market access function working in close coordination with clinical development.
The CEO participates in launch planning at the strategic level: reviewing the overall launch strategy including market access positioning, approving major investments in pre-launch access development, and making the final pricing decisions for significant new launches.
The pre-launch market access work itself, which includes hundreds of hours of payer research, dossier writing, and early engagement activities, is entirely the market access team’s responsibility.
Pricing Policy and Government Affairs Integration
Pharmaceutical pricing is a government relations issue as well as a commercial issue. The pricing and market access function must work closely with the government affairs and corporate affairs team to ensure that pricing decisions and public policy positions are coherent.
The CEO coordinates this integration at the leadership level: ensuring that the head of market access and the head of government affairs have a regular communication rhythm, and that pricing strategy considerations inform government affairs positioning and vice versa.
This coordination is particularly important when major legislative or regulatory developments are affecting the pricing environment. The CEO brings the strategic perspective that integrates the commercial and policy dimensions.
According to McKinsey, pharmaceutical companies with integrated market access strategies that coordinate pricing, health economics, government affairs, and patient advocacy consistently achieve better reimbursement outcomes and faster patient access than those managing these functions in silos.
Managing International Pricing Complexity
Pharmaceutical pricing in international markets involves a complex web of country-specific reimbursement systems, reference pricing relationships between countries, and regulatory requirements. International pricing management is a specialized function requiring dedicated expertise.
A Head of International Market Access or International Pricing Director should manage this function. They oversee pricing strategies for each major market, manage the reference pricing implications of pricing decisions across markets, and coordinate with country-level commercial teams on market-specific access strategies.
The CEO engages with international pricing at the strategic level: major market entry decisions that have pricing implications, significant reimbursement negotiations in priority markets, and the overall international pricing philosophy that guides country-level decisions.
See pharma product launch for how pricing and market access delegation integrates with the broader launch management framework.
Building Pricing Decision Governance
Pharmaceutical pricing decisions require a governance structure that is clear enough to be efficient and robust enough to prevent poor decisions. Build a pricing governance committee that brings together the relevant functional perspectives: commercial, market access, medical affairs, legal, finance, and government affairs.
This committee reviews pricing analyses, debates strategic options, and makes recommendations. For major pricing decisions, the recommendation goes to the CEO for final approval. For routine pricing matters within established parameters, the committee makes decisions independently.
The CEO chairs or regularly participates in major pricing governance discussions. They do not attend routine pricing committee meetings. This structure ensures that pricing decisions benefit from cross-functional perspective without requiring CEO involvement in every pricing question across the portfolio.
Conclusion
Pharmaceutical pricing and market access requires CEO-level ownership of strategy, philosophy, and major decisions, paired with functional delegation of analytical work, payer relationship management, access program operations, and policy monitoring. The CEO who builds a strong pricing and market access function, defines the governance structure for major decisions, and maintains the philosophical leadership on patient access can drive both commercial performance and organizational integrity on one of the industry’s most visible and sensitive responsibilities.
Build the function, define the governance, and lead the philosophy. Delegate the execution.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.